Compare Adaptive Biotechnologies Corp (ADPT) vs Snowflake Inc (SNOW) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Snowflake Inc — how do they compare? Adaptive Biotechnologies Corp trades at $20.12 (market cap $3.33B), while Snowflake Inc trades at $259.4 (market cap $91.07B). The key difference: Snowflake Inc is far larger — about 27.3× Adaptive Biotechnologies Corp's market cap. Which is the better fit depends on your goals.
| ADPT | SNOW | |
|---|---|---|
Market Cap | $3.33B | $91.07B |
Sector | Health | Technology |
52-Week High | $22.37 | $280.16 |
52-Week Low | $10.24 | $121.11 |
Enterprise Value | $3.19B | $90.88B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
SNOW trades at $262.74, up 1.0% today, with a bullish technical outlook from moving averages and strong analyst consensus. The stock shows accelerating revenue growth, reaching $3.63B in 2025, but remains unprofitable with a net income margin of -23.79%. Recent news highlights AI Data Cloud traction and partnerships driving optimism, while cash flow from operations improved to $959.76M.
Outlook is positive due to AI-driven growth and consistent earnings beats, but high valuation (P/S 17.74) and persistent losses pose risks. Wall Street's $294.31 price target suggests ~12% upside, though competition and execution challenges require monitoring for sustained shareholder value.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Snowflake Inc
Founded in 2012, Snowflake is a data lake, warehousing, and sharing company that came public in 2020. To date, the company has over 3,000 customers including nearly 30% of the Fortune 500 as its customers. Snowflake's data lake stores unstructured and semistructured data that can then be used in analytics to create insights stored in its data warehouse. Snowflake's data sharing capability allows enterprises to easily buy and ingest data almost instantaneously compared with a traditionally months-long process. Overall, the company is known for the fact that all of its data solutions that can be hosted on various public clouds.
Read more on SNOW →
